Workflow
Boston Scientific(BSX)
icon
Search documents
What's Happening With Boston Scientific Stock?
Forbes· 2025-06-16 15:00
Core Insights - Boston Scientific has seen a stock price increase of over 30% in the last twelve months, significantly outperforming the S&P 500's gain of 9% due to new product launches that enhanced sales growth and profit margins [2] - The current valuation of Boston Scientific appears relatively overpriced compared to the broader market and its historical performance metrics [2] Valuation Compared to the S&P 500 - Boston Scientific's price-to-sales (P/S) ratio is 8.3, compared to the S&P 500's 3.0 - The price-to-free cash flow (P/FCF) ratio is 38.0, significantly higher than the benchmark's 20.5 - The price-to-earnings (P/E) ratio stands at 71.4, while the S&P 500's is 26.4, indicating a considerable premium for Boston Scientific's sales, profits, and cash flow [3] Revenue Growth Performance - Boston Scientific's revenues have increased at an average rate of 13.1% over the past three years, outpacing the S&P 500's rise of 5.5% - Revenues increased by 19.4% over the past twelve months, from $15 billion to $18 billion - Quarterly revenues rose by 20.9%, growing from $3.9 billion to $4.7 billion compared to the previous year [4] Profitability Analysis - The operating income over the past four quarters totaled $3.2 billion, yielding an operating margin of 18.5%, exceeding the S&P 500's 13.2% - Operating Cash Flow (OCF) for the same period was $3.8 billion, reflecting an OCF margin of 21.7%, compared to the S&P 500's 14.9% - Net Income over the last four quarters was $2.0 billion, resulting in a net income margin of 11.6%, aligning with the average of the S&P 500 [5] Financial Stability - Boston Scientific's debt stands at $12 billion against a market capitalization of $147 billion, resulting in a Debt-to-Equity Ratio of 8.1%, lower than the S&P 500's 19.9% - Cash and cash equivalents total $725 million, yielding a Cash-to-Assets Ratio of 1.8% compared to total assets of $40 billion, significantly lower than the S&P 500's 13.8% [6] Resilience During Downturns - During the "Inflation Shock" of 2022, BSX stock declined by 25.2%, similar to the S&P 500's decrease of 25.4%, but fully recovered by December 2022 - The COVID-19 pandemic caused BSX stock to drop 43.5%, compared to a 33.9% fall for the S&P 500, with recovery by August 2021 - The Global Financial Crisis of 2008 saw BSX stock plunge 70.5%, compared to the S&P 500's decline of 56.8%, with recovery taking until November 2015 [7] Conclusion and Outlook - Boston Scientific demonstrates "Extremely Strong" growth, "Strong" profitability, and a "Neutral" financial stability profile - The stock's "Weak" resilience during downturns and "Very High" valuation contribute to an "Overall Neutral" evaluation - The current price-to-sales ratio of 8.3x is significantly higher than the historical average of 5.9x, indicating the stock is trading at a substantial premium [8] Investment Alternatives - For investors seeking upside with reduced volatility, portfolios like the Trefis High Quality (HQ) portfolio and Reinforced Value (RV) Portfolio provide alternatives, with the HQ Portfolio having outperformed the S&P 500 over the last four years [9]
Why the Market Dipped But Boston Scientific (BSX) Gained Today
ZACKS· 2025-06-13 23:01
Group 1: Stock Performance - Boston Scientific (BSX) closed at $99.74, marking a +1.2% move from the prior day, outperforming the S&P 500's daily loss of 1.13% [1] - Over the last month, BSX shares have decreased by 6.01%, underperforming the Medical sector's gain of 3.07% and the S&P 500's gain of 3.55% [1] Group 2: Upcoming Earnings - Boston Scientific is projected to report earnings of $0.72 per share, representing year-over-year growth of 16.13% [2] - The Zacks Consensus Estimate for revenue is projecting net sales of $4.89 billion, up 18.63% from the year-ago period [2] Group 3: Annual Forecast - For the entire year, the Zacks Consensus Estimates forecast earnings of $2.91 per share and revenue of $19.49 billion, indicating changes of +15.94% and +16.4%, respectively, compared to the previous year [3] Group 4: Analyst Estimates - Recent changes to analyst estimates for Boston Scientific reflect shifting dynamics of short-term business patterns, with positive revisions indicating analysts' confidence in business performance and profit potential [4] Group 5: Zacks Rank and Valuation - The Zacks Rank system, which includes estimate changes, currently ranks Boston Scientific at 3 (Hold) [6] - Boston Scientific is trading with a Forward P/E ratio of 33.83, compared to the industry average of 19.2, indicating a premium valuation [7] Group 6: PEG Ratio and Industry Ranking - Boston Scientific has a PEG ratio of 2.55, while the industry average PEG ratio is 2.28 [8] - The Medical - Products industry has a Zacks Industry Rank of 146, placing it within the bottom 41% of over 250 industries [8]
BSX Q1 Endoscopy Sales Rise 6%: What's Behind the Growth?
ZACKS· 2025-06-13 13:20
Core Insights - Boston Scientific's Endoscopy business is strategically positioned to benefit from the expanding global endoscopy devices market, which is projected to grow from $28.1 billion in 2022 to $44.1 billion by 2032 at a CAGR of 4.6% from 2023 to 2032 [1] Company Performance - Sales of Endoscopy products reached $673 million in Q1 2025, reflecting a 6% increase both operationally and organically, accounting for 14% of the company's overall revenues [2][8] - The growth in sales is attributed to steady performance across geographies and a diverse product suite, with notable double-digit growth in the AXIOS Stent and Electrocautery Enhanced Delivery System [3][8] - The Endoluminal Surgery franchise also experienced double-digit growth driven by innovative technologies such as OverStitch and MANTIS Clip, indicating strong adoption of advanced endoscopic tools [4] Competitive Landscape - Stryker's Endoscopy segment reported a strong 11.1% increase in U.S. organic sales, driven by double-digit gains in core endoscopy and sports medicine portfolios [5] - Johnson & Johnson, through its subsidiary Ethicon, is a key competitor, focusing on advanced energy-based endoscopic surgery platforms and digital surgery initiatives [6] Stock Performance - Boston Scientific's shares have increased by 27.3% over the past year, outperforming the industry growth of 9.7% and the S&P 500's growth of 11% during the same period [7] Valuation Metrics - The company trades at a forward 12-month price-to-earnings ratio (P/E) of 32.13X, which is above the industry average of 21.33X [9] Earnings Estimates - The Zacks Consensus Estimate for Boston Scientific's earnings has been on the rise over the past 60 days, indicating positive sentiment regarding future performance [11]
畅联股份:与泡泡玛特等多家世界500强企业有合作关系
news flash· 2025-06-13 09:29
Core Viewpoint - Changlian Co., Ltd. has established long-term strategic partnerships with several Fortune 500 companies, including Pop Mart and other industry leaders [1] Company Partnerships - The company has formed collaborations with notable firms such as Apple, BD, BOC Healthcare, Seiko, Mitsubishi, Hissen Meikang, Jaguar Land Rover, Baxter, and Kobayashi [1]
Cardiovascular Tailwind Boosts BSX: Here's How to Play the Stock
ZACKS· 2025-06-10 13:55
Core Insights - Boston Scientific (BSX) is strategically positioned to benefit from the expanding cardiovascular devices market, which is projected to grow from $72.83 billion in 2023 at a CAGR of 7.3% from 2024 to 2029 [1][2] - The company's strong performance in Q1 2025, with a revenue increase of 22.2% and adjusted EPS growth of 34%, reflects its leadership in the cardiovascular segment [6][7] - BSX's stock has outperformed the broader Medical Product industry and key competitors, with a 31.8% increase over the past year [3] Market Performance - The cardiovascular devices market is experiencing growth due to aging demographics, minimally invasive procedures, and technological innovations [2] - Boston Scientific's Electrophysiology business has seen organic growth of 145%, making it the second-largest player in this space [8] - The company reported a 26.2% year-over-year increase in cardiovascular segment sales, with U.S. revenues rising by 31% [6][9] Financial Outlook - For full-year 2025, Boston Scientific raised its organic revenue growth guidance to 12-14% and expects adjusted EPS of $2.87-$2.94, indicating a year-over-year growth of 14-17% [11] - The Zacks Consensus Estimate for BSX's 2025 sales and EPS suggests a year-over-year improvement of 16.4% and 15.9%, respectively [12] Product Performance - The WATCHMAN device sales grew by 24% year over year, supported by procedural growth and new product versions [10] - The FARAPULSE system is gaining traction globally, contributing to the rapid expansion of BSX's market share in Electrophysiology [8][9] Competitive Positioning - Boston Scientific's shares are trading at a forward P/E of 33.31X, which is above the industry average of 21.29X, indicating a premium valuation [15] - The company is expected to continue delivering shareholder value through strong operational performance and growth in key segments [17][18]
Boston Scientific (BSX) Upgraded to Buy: Here's Why
ZACKS· 2025-06-06 17:01
Core Viewpoint - Boston Scientific (BSX) has received an upgrade to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on a company's changing earnings picture, specifically the consensus of EPS estimates from sell-side analysts [1][2]. - Changes in future earnings potential, reflected in earnings estimate revisions, are strongly correlated with near-term stock price movements, particularly due to institutional investors' reliance on these estimates for valuation [4][6]. Business Outlook and Investor Sentiment - The rising earnings estimates and the Zacks rating upgrade for Boston Scientific indicate an improvement in the company's underlying business, suggesting that investors may respond positively by pushing the stock price higher [5][10]. - Boston Scientific is projected to earn $2.91 per share for the fiscal year ending December 2025, representing a year-over-year change of 15.9%, with a 2.3% increase in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7][9]. - The upgrade of Boston Scientific to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
ZACKS· 2025-06-04 15:35
Demographic Trends - The global population is aging rapidly, with life expectancies increasing and birth rates declining, leading to a demographic imbalance in both developed and emerging economies [1] - By 2030, one in six individuals globally will be over 60, and by 2050, this figure is expected to reach 2.1 billion, with 80% residing in low- and middle-income countries [2] Healthcare Market Dynamics - The global geriatric care market was valued at approximately $1.2 trillion in 2025, up from around $1 trillion in 2022, driven by the rising prevalence of chronic conditions among older adults [3] - There is a growing demand for pharmaceuticals, medical devices, home-based care, and digital health solutions tailored for aging populations [3] Company Strategies - Healthcare companies like Boston Scientific, AbbVie, Amgen, and Dexcom are enhancing operational efficiency to expand their presence in the Seniors & Aging Demographics domain [4] - Pharmaceutical companies are focusing on developing treatments for chronic conditions prevalent in older adults, particularly in immunology, oncology, and neurodegenerative diseases [5] Investment Opportunities - The Healthcare Real Estate Investment Trust (Healthcare REIT) sector is gaining attention, with companies like Community Healthcare Trust and CareTrust REIT focusing on specialized healthcare real estate for the aging population [6] - Digital health solutions, AI-driven diagnostics, and home-based monitoring systems are creating new revenue opportunities for healthcare firms [5] Company Highlights - Boston Scientific has developed devices like the WATCHMAN and SYNERGY systems, catering to the needs of elderly patients [8] - AbbVie is expanding its focus on the aging demographic through strategic acquisitions and partnerships, including the acquisition of Aliada Therapeutics for Alzheimer's treatment [10][11] - Amgen is advancing its R&D pipeline with a focus on elderly-targeted medicines, including osteoporosis treatments and obesity drugs [13][14][15] - Dexcom is enhancing its continuous glucose monitoring systems for seniors, including the launch of the Stelo system, which is designed for ease of use [16][17]
Emerging Markets Power Boston Scientific: Will the Growth Trend Continue?
ZACKS· 2025-06-04 14:06
Core Insights - Emerging markets are crucial for Boston Scientific Corporation's (BSX) growth strategy, with a 9.8% year-over-year operational sales growth in Q1 2025 despite geopolitical challenges [1][8] - The medical device industry is experiencing strong growth opportunities in emerging markets, driven by trends such as preventive healthcare and digital health adoption [2] - Boston Scientific's sustained investment and localized strategies position it well to capture future growth in these high-potential regions [3] Emerging Market Performance - BSX's emerging market operations delivered robust sales growth of approximately 9.8% year over year in Q1 2025, supported by favorable economic trends and expanding healthcare infrastructure [1][8] - India’s medical device market is projected to grow from $15.35 billion in 2023 to $20.51 billion by 2029, reflecting a CAGR of 5.35% [2] - China and Brazil are highlighted as key markets due to their large populations and expanding economies, with Southeast Asian countries also gaining importance [2] Competitive Landscape - Competition in emerging markets is intense, with Abbott Laboratories and Medtronic actively expanding their global reach [4] - Abbott's Established Pharmaceuticals Division, focused on emerging markets, reported high single-digit organic growth in Q1 2025, driven by strong demand across Asia, Latin America, and the Middle East [5] - Medtronic generated nearly 49% of its revenues from international markets, with mid-single-digit growth in its emerging market business, particularly in India and Southeast Asia [6] Financial Performance - BSX shares have increased by 35.8% over the past year, outperforming the industry growth of 9.6% and the S&P 500's growth of 12.2% [7][8] - The company trades at a forward price-to-earnings ratio of 33.69, which is above the industry average of 21.73 [9] - The Zacks Consensus Estimate for BSX's earnings has been rising, indicating positive sentiment among analysts [10]
多款创新器械和药物亮相东方会,心血管疗法有望打破“姑息治疗”
Di Yi Cai Jing· 2025-05-31 10:26
在心血管领域的治疗方面,过去临床上很多疗法都是姑息治疗,例如心衰或者严重的瓣膜疾病,很多时候患者来就医时,疾病已经发展到终末期了,没有很 好的治疗方法。 在PCI治疗诊断领域,血管内超声(IVUS)有"黄金眼"之称,对于优化医生在PCI治疗中的评估起到关键作用。借助于人工智能技术的发展,IVUS系统的诊 断精准性得到了进一步的提升。 5月31日,波士顿科学公司用于冠心病诊疗的IVUS诊断系统AVVIGO+正式发布,该系统具备人工智能辅助血管评估功能,可自动实现关键步骤的操作实 施,并提供直观、精确的血管测量数据,显著缩短操作时间。波士顿科学公司数据显示,相比于上一代血管内超声诊断系统,新一代系统可以减少62%的操 作时间。 此外,该系统同时整合了血流储备分数(FFR)和舒张期无充血比率(DFR)测量功能,能帮助评估冠状动脉内部阻塞和狭窄的严重程度,为精准治疗提供 决策依据。 在第十九届东方心脏病学会议OCC 2025(下称:东方会)上,包括全球首款介入主动脉预装干瓣、新一代血管内超声(IVUS)诊断系统、全球首款长效 PCSK9单抗在内的多款创新医疗器械和药品正式发布上市,为心血管疾病诊疗带来创新解决方案。 ...
Boston Scientific: Old, Reliable; Buy For Their Consistent Growth
Seeking Alpha· 2025-05-30 08:45
Industry Overview - The medical device industry is central to delivering effective healthcare outcomes through advanced technology and engineering [1] - Key innovations include minimally invasive surgical tools, wearable technologies, and enhanced robotic capabilities [1] Company Highlights - Several standout companies are leading the advancements in the medical device sector [1]